Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Sleep Difficulties in Preschoolers with Psychiatric Diagnoses.

Chénier-Leduc G, Béliveau MJ, Dubois-Comtois K, Butler B, Berthiaume C, Pennestri MH.

Int J Environ Res Public Health. 2019 Nov 14;16(22). pii: E4485. doi: 10.3390/ijerph16224485.

2.

A Fanci knockout mouse model reveals common and distinct functions for FANCI and FANCD2.

Dubois EL, Guitton-Sert L, Béliveau M, Parmar K, Chagraoui J, Vignard J, Pauty J, Caron MC, Coulombe Y, Buisson R, Jacquet K, Gamblin C, Gao Y, Laprise P, Lebel M, Sauvageau G, D d'Andrea A, Masson JY.

Nucleic Acids Res. 2019 Aug 22;47(14):7532-7547. doi: 10.1093/nar/gkz514.

3.

Resolution of diagnosis and parental attitudes among parents of adolescent kidney recipients.

Leblond M, Achille M, Béliveau MJ, Clermont MJ, Blydt-Hansen T.

Pediatr Transplant. 2019 Aug;23(5):e13472. doi: 10.1111/petr.13472. Epub 2019 May 12.

PMID:
31081267
4.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Cortes J, Massard C, Armand JP, Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy532. [Epub ahead of print] No abstract available.

PMID:
30624604
5.

A Randomized, First-in-Human, Healthy Volunteer Trial of sutimlimab, a Humanized Antibody for the Specific Inhibition of the Classical Complement Pathway.

Bartko J, Schoergenhofer C, Schwameis M, Firbas C, Beliveau M, Chang C, Marier JF, Nix D, Gilbert JC, Panicker S, Jilma B.

Clin Pharmacol Ther. 2018 Oct;104(4):655-663. doi: 10.1002/cpt.1111. Epub 2018 Jul 13.

6.

Effect of manufacturing and experimental conditions on the mechanical and surface properties of silicone elastomer scaffolds used in endothelial mechanobiological studies.

Campeau MA, Lortie A, Tremblay P, Béliveau MO, Dubé D, Langelier È, Rouleau L.

Biomed Eng Online. 2017 Jul 14;16(1):90. doi: 10.1186/s12938-017-0380-5.

7.

Fifty-year spatiotemporal analysis of landscape changes in the Mont Saint-Hilaire UNESCO Biosphere Reserve (Quebec, Canada).

Béliveau M, Germain D, Ianăş AN.

Environ Monit Assess. 2017 May;189(5):215. doi: 10.1007/s10661-017-5938-y. Epub 2017 Apr 14.

PMID:
28411319
8.

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3-1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer.

Thomas M, Sadjadian P, Kollmeier J, Lowe J, Mattson P, Trout JR, Gargano M, Patchen ML, Walsh R, Beliveau M, Marier JF, Bose N, Gorden K, Schneller F 3rd.

Invest New Drugs. 2017 Jun;35(3):345-358. doi: 10.1007/s10637-017-0450-3. Epub 2017 Mar 16.

9.

Public health surveillance response following the southern Alberta floods, 2013.

Sahni V, Scott AN, Beliveau M, Varughese M, Dover DC, Talbot J.

Can J Public Health. 2016 Aug 15;107(2):e142-8. doi: 10.17269/cjph.107.5188.

PMID:
27526210
10.

[Fanconi anemia animal models - How differences can teach us as much as similarities…].

Dubois ÉL, Béliveau M, Masson JY.

Med Sci (Paris). 2016 Jun-Jul;32(6-7):598-605. doi: 10.1051/medsci/20163206023. Epub 2016 Jul 12. Review. French.

11.

Organizational Change, Leadership, and the Transformation of Continuing Professional Development: Lessons Learned From the American College of Cardiology.

Beliveau ME, Warnes CA, Harrington RA, Nishimura RA, O'Gara PT, Sibley JB, Oetgen WJ.

J Contin Educ Health Prof. 2015 Summer;35(3):201-10. doi: 10.1002/chp.21301.

PMID:
26378426
12.

An exploration of the ecological validity of the Virtual Action Planning-Supermarket (VAP-S) with people with schizophrenia.

Aubin G, Béliveau MF, Klinger E.

Neuropsychol Rehabil. 2018 Jul;28(5):689-708. doi: 10.1080/09602011.2015.1074083. Epub 2015 Aug 28.

PMID:
26317526
13.

Behavior problems of children in foster care: Associations with foster mothers' representations, commitment, and the quality of mother-child interaction.

Dubois-Comtois K, Bernier A, Tarabulsy GM, Cyr C, St-Laurent D, Lanctôt AS, St-Onge J, Moss E, Béliveau MJ.

Child Abuse Negl. 2015 Oct;48:119-30. doi: 10.1016/j.chiabu.2015.06.009. Epub 2015 Jul 15.

PMID:
26187685
14.

Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.

Gunawardana M, Remedios-Chan M, Miller CS, Fanter R, Yang F, Marzinke MA, Hendrix CW, Beliveau M, Moss JA, Smith TJ, Baum MM.

Antimicrob Agents Chemother. 2015 Jul;59(7):3913-9. doi: 10.1128/AAC.00656-15. Epub 2015 Apr 20.

15.

Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.

Cortez JM Jr, Quintero R, Moss JA, Beliveau M, Smith TJ, Baum MM.

Antimicrob Agents Chemother. 2015 Jan;59(1):59-66. doi: 10.1128/AAC.03906-14. Epub 2014 Oct 13.

16.

Clinical pearls in perioperative medicine.

Beliveau M, Bundrick JB.

Dis Mon. 2014 Jul;60(7):402-11. doi: 10.1016/j.disamonth.2014.04.018. Review. No abstract available.

PMID:
24951011
17.

Physician competence: a perspective from the practicing cardiologist.

Beliveau ME, Nishimura RA, O'Gara P.

Methodist Debakey Cardiovasc J. 2014 Jan-Mar;10(1):50-2.

18.

Update on the American Board of Internal Medicine Maintenance of Certification Program: a report of the American College of Cardiology's Educational Quality Review Board.

Ting HH, Bates ER, Beliveau ME, Drozda JP Jr, Harold JG, Krumholz HM, Nishimura RA, Oetgen WJ, Sibley JB, Tcheng JE.

J Am Coll Cardiol. 2014 Jan 7-14;63(1):92-100. doi: 10.1016/j.jacc.2013.10.002. Review. No abstract available.

19.

Comparison of the quality of patient referrals from physicians, physician assistants, and nurse practitioners.

Lohr RH, West CP, Beliveau M, Daniels PR, Nyman MA, Mundell WC, Schwenk NM, Mandrekar JN, Naessens JM, Beckman TJ.

Mayo Clin Proc. 2013 Nov;88(11):1266-71. doi: 10.1016/j.mayocp.2013.08.013. Epub 2013 Oct 9.

PMID:
24119364
20.

Bulleidia extructa periprosthetic hip joint infection, United States.

Kloesel B, Beliveau M, Patel R, Trousdale RT, Sia IG.

Emerg Infect Dis. 2013 Jul;19(7):1170-1. doi: 10.3201/eid1907.130078. No abstract available.

21.

President's page: Lifelong learning in the digital age.

Zoghbi WA, Beliveau ME.

J Am Coll Cardiol. 2012 Sep 4;60(10):944-6. doi: 10.1016/j.jacc.2012.07.016. No abstract available.

22.

Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate.

Lichter-Konecki U, Diaz GA, Merritt JL 2nd, Feigenbaum A, Jomphe C, Marier JF, Beliveau M, Mauney J, Dickinson K, Martinez A, Mokhtarani M, Scharschmidt B, Rhead W.

Mol Genet Metab. 2011 Aug;103(4):323-9. doi: 10.1016/j.ymgme.2011.04.013. Epub 2011 May 5.

23.

Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, Baselga J.

Ann Oncol. 2012 Feb;23(2):463-71. doi: 10.1093/annonc/mdr137. Epub 2011 May 16.

PMID:
21576284
24.

Dose response of bone-targeted enzyme replacement for murine hypophosphatasia.

Yadav MC, Lemire I, Leonard P, Boileau G, Blond L, Beliveau M, Cory E, Sah RL, Whyte MP, Crine P, Millán JL.

Bone. 2011 Aug;49(2):250-6. doi: 10.1016/j.bone.2011.03.770. Epub 2011 Mar 31.

25.

The value of testicular 'mapping' in men with non-obstructive azoospermia.

Beliveau ME, Turek PJ.

Asian J Androl. 2011 Mar;13(2):225-30. doi: 10.1038/aja.2010.178. Epub 2011 Jan 24. Review.

26.

Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.

Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, Marier JF, Beliveau M, Mauney J, Dickinson K, Martinez A, Gargosky S, Mokhtarani M, Berry SA.

Mol Genet Metab. 2010 Jul;100(3):221-8. doi: 10.1016/j.ymgme.2010.03.014. Epub 2010 Mar 23.

27.

Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease.

Marier JF, Mouksassi MS, Gosselin NH, Beliveau M, Cyran J, Wallens J.

J Clin Pharmacol. 2010 Jan;50(1):36-49. doi: 10.1177/0091270009342252. Epub 2009 Sep 22.

PMID:
19773525
28.

Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.

Babbar S, Marier JF, Mouksassi MS, Beliveau M, Vanhove GF, Chanda S, Bley K.

Ther Drug Monit. 2009 Aug;31(4):502-10. doi: 10.1097/FTD.0b013e3181a8b200.

PMID:
19494795
29.

Pharmacokinetics, safety, and tolerability of teduglutide, a glucagon-like peptide-2 (GLP-2) analog, following multiple ascending subcutaneous administrations in healthy subjects.

Marier JF, Beliveau M, Mouksassi MS, Shaw P, Cyran J, Kesavan J, Wallens J, Zahir H, Wells D, Caminis J.

J Clin Pharmacol. 2008 Nov;48(11):1289-99. doi: 10.1177/0091270008320605.

PMID:
18974283
30.
31.

Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals.

Béliveau M, Lipscomb J, Tardif R, Krishnan K.

Chem Res Toxicol. 2005 Mar;18(3):475-85.

PMID:
15777087
32.

Molecular structure-based prediction of the steady-state blood concentrations of inhaled organics in rats.

Béliveau M, Krishnan K.

Toxicol Mech Methods. 2005;15(5):361-6. doi: 10.1080/15376520500195921.

PMID:
20021057
33.
34.

Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures.

Krishnan K, Haddad S, Béliveau M, Tardif R.

Environ Health Perspect. 2002 Dec;110 Suppl 6:989-94. Review.

35.

Perioperative care for the elderly patient.

Beliveau MM, Multach M.

Med Clin North Am. 2003 Jan;87(1):273-89. Review.

PMID:
12575895
36.

A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures.

Haddad S, Béliveau M, Tardif R, Krishnan K.

Toxicol Sci. 2001 Sep;63(1):125-31.

PMID:
11509752
37.

Blood:air partition coefficients of individual and mixtures of trihalomethanes.

Béliveau M, Charest-Tardif G, Krishnan K.

Chemosphere. 2001 Jul;44(3):377-81.

PMID:
11459142
38.

Quantitative structure-pharmacokinetic relationship modelling.

Fouchécourt MO, Béliveau M, Krishnan K.

Sci Total Environ. 2001 Jul 2;274(1-3):125-35.

PMID:
11453289
39.
40.

Concentration dependency of rat blood: air partition coefficients of some volatile organic chemicals.

Béliveau M, Krishnan K.

J Toxicol Environ Health A. 2000 Jul 28;60(6):377-89.

PMID:
10933755
41.

The human 5-hydroxytryptamine 1A receptor differentially modulates phospholipase C and adenylyl cyclase activities.

Fenrick R, Pou C, Beliveau M, Fargin A.

Gen Pharmacol. 1996 Mar;27(2):263-8.

PMID:
8919640
42.

Immunochemical and genetic studies in two bisalbuminemic families.

Margni RA, Heer EE, Acerbo E, Hajos S, Beliveau M, Bobbi ME.

Clin Chim Acta. 1970 Aug;29(2):219-25. No abstract available.

PMID:
5531209

Supplemental Content

Loading ...
Support Center